on GENSIGHT BIOLOGICS S.A. (EPA:SIGHT)
GenSight Biologics Discloses Cash Position, Advances on LUMEVOQ®
GenSight Biologics reported cash of €3.4 million as of September 30, 2024, down significantly from €6.9 million in June. The company does not have sufficient funds to last 12 months, but anticipates payments by January 2025 thanks to the resumption of the compassionate access program (CAP). Discussions are underway to raise funds before mid-November. Waivers have been obtained from creditors, facilitating financing options.
LUMEVOQ® production is complete and compliant with standards. GenSight will submit a dossier to ANSM in November to restart the AAC program, with treatments planned for the end of December. The company is preparing to meet ANSM requirements.
R. H.
Copyright © 2024 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all GENSIGHT BIOLOGICS S.A. news